OBJECTIVES

: There is currently only one treatment option available for patients with moderate-to-severe atopic dermatitis who are intolerant or refractory to conventional topical and/or systemic treatments. The purpose of this analysis is to assess the population health benefits of introducing new treatment options for these patients. The hypothesis is that as the number of treatment options increases, the share of patients in disease control will increase.

METHODS

: A model was developed to evaluate the marginal impact in treatment years. A decision-tree structure was applied with treatment cycles of four weeks. The model estimated treatment success in a population of 1,000 patients over 10-years. More specifically, we analysed treatment lines that included dupilumab and tralokinumab. Patients are anticipated to switch to next-in-line treatment if they did not achieve EASI 50 after 16 weeks of treatment. After the induction period it was assumed that patients would discontinue treatments gradually with a discontinuation rate of 1% per four week cycle.

RESULTS

: More patients would be in control if several treatment options were available. With only one treatment option available (dupilumab) and 1,000 patients, the total number of treatment years would be 4,373 corresponding to 56% of the patient years being left untreated over a 10-year period. By introducing more new treatment options the total number of treatment years would increase. Introducing tralokinumab to the model could increase the number of treatment years to 6,513 independent of treatment sequence.

CONCLUSIONS

: Introducing a second biologic treatment option will be a great benefit for patients with atopic dermatitis. Moreover, three or more treatment options will further increase the number of treatment years. Therefore, it is important to have more biologic treatment options for patients with moderate-to-severe atopic dermatitis to reduce the number of untreated patient years.